... fats
LDL
Chylomicron
Cholesterol
Liver cell
Lipoprotein
synthesis
Cholesterol
Triglycerides
Synthesis
Cholesterol-
ester
Triglycerides
B. Cholesterol metabolism in liver cell and cholesterol-lowering drugs
Bile acids Lipoproteins
HMG-CoA-Reductase ... nonfunc-
tional and needed to be replaced by de
novo synthesis. A particular adverse ef-
fect results from interference with gon-
adal hormon...
... ac-
cumulation will vary. The elimination of
salicylate, the rapidly formed metab-
olite of ASA, is notable for its dose de-
pendence. Salicylate is effectively reab-
sorbed in the kidney, except ... ischemic necrosis
of the endometrium preceding men-
struation. The relative proportions of in-
dividual PG are said to be altered in dys-
menorrhea and excessive menstrual
bleeding.
Ute...
... course of therapy, progressively
larger doses are needed to achieve the
same degree of pain relief. Development
of tolerance does not involve the pe-
ripheral effects, so that persistent con-
stipation ... required plas-
ma level with the attending risk of un-
wanted toxic effects and tolerance de-
velopment. Preferred alternatives in-
clude the use of controlled-release
preparati...
... the
!-cell membrane by closing off ATP-gat-
ed K
+
channels. Normally, these chan-
nels are closed when intracellular levels
of glucose, hence of ATP, increase. This
drug class includes tolbutamide ... deriva-
tive, can lower excessive blood glucose
levels, provided that insulin is present.
Metformin does not stimulate insulin re-
lease. Glucose release from the liver is
decreased, while...